EEI-BIOTECHFINANCES Eléments Essentiels d'Information / Essential Elements of Information
Saturday, March 30th 2019 at 12:00pm UTC – Pre-clinical Data Characterize the Conditional and Potent Activity of the Company’s Novel COBRATM Platform, a Conditionally Active T-cell Engaging Therapeutic Designed to Target Solid Tumors – BRISBANE, Calif.–(BUSINESS WIRE)– Maverick Therapeutics Inc., a private biopharmaceutical company pioneering next-generation redirected T-cell targeted immunotherapies, …
Plus »Forbius’ AVID100, a Novel Anti-EGFR ADC, Reports Positive Phase 1 Data at AACR: Exceptionally High RP2D Established, Phase 2 in SCCHN and sqNSCLC Ongoing
Friday, March 29th 2019 at 7:44pm UTC AVID100 is the only clinical-stage anti-EGFR ADC that targets both wild-type and mutant forms of EGFR with limited off-tumor toxicity due to novel mechanism of action Phase 1 confirmed that AVID100 was well-tolerated and established a recommended phase 2 dose (RP2D) of 220 …
Plus »Celularity Announces Results of Phase 1 Studies of PNK-007, an Allogeneic, Off-the-Shelf, Placental-Derived Cell Therapy, at AACR Annual Meeting 2019
Friday, March 29th 2019 at 7:15pm UTC First-ever Results to be Presented from Multiple Studies Evaluating Company’s PNK Allogeneic Cell Therapy in Patients with Acute Myeloid Leukemia and Multiple Myeloma WARREN, N.J.–(BUSINESS WIRE)– Celularity, Inc. (“Celularity” or the “Company”), a clinical-stage cell therapeutics company developing allogeneic cellular therapies harnessed from …
Plus »Northern Biologics Reports Initial Phase I Data for MSC-1 at AACR
Friday, March 29th 2019 at 7:01pm UTC TORONTO–(BUSINESS WIRE)– Northern Biologics Inc., a company focused on developing first-in-class immuno-oncology products, today announced the presentation of initial results from the Phase I trial of their lead antibody, MSC-1, at the American Association for Cancer Research meeting in Atlanta, Georgia. Session Title: …
Plus »Preliminary Data from Phase 1 Study Evaluating ADXS-NEO Suggest Rapid Immunogenicity and Clinical Activity
Friday, March 29th 2019 at 7:00pm UTC Data to be Presented at AACR Annual Meeting PRINCETON, N.J.–(BUSINESS WIRE)– Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of ADXS-NEO data in a poster discussion entitled “Safety and Immunogenicity of …
Plus »Definiens et Ultivue annoncent une collaboration visant à développer des offres conjointes dans le domaine de l’immunofluorescence multiplexe et de l’analyse d’image numérique par intelligence artificielle
Friday, March 29th 2019 at 6:03pm UTC CAMBRIDGE, Massachusetts–(BUSINESS WIRE)– Ultivue, un développeur de tests d’identification et de quantification des biomarqueurs tissulaires destinés aux laboratoires de recherche translationnelle et en pathologie, et Definiens, une société pionnière de l’analyse des images basée sur l’intelligence artificielle, ont annoncé aujourd’hui une collaboration visant …
Plus »Groupe Santé Devonian émet des titres en règlement des intérêts dûs aux détenteurs de débentures et octroie des options
Friday, March 29th 2019 at 6:00pm UTC CE COMMUNIQUÉ NE DOIT PAS ÊTRE DIFFUSÉ, PUBLIÉ OU DISTRIBUÉ, EN TOUT OU EN PARTIE, AUX ÉTATS-UNIS QUÉBEC–(BUSINESS WIRE)– Groupe Santé Devonian Inc. (la « Société » ou « Devonian ») (Bourse de croissance TSX : GSD), une société biopharmaceutique au stade clinique, annonce l’émission des titres suivants en …
Plus »Devonian Health Group Issues Securities in Interest Settlement Due to Debenture Holders and Grants Options
Friday, March 29th 2019 at 6:00pm UTC NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN THE UNITED STATES. QUEBEC–(BUSINESS WIRE)– Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV:GSD), a clinical stage biopharmaceutical corporation, today announces the issuance of the following securities in consideration of interest …
Plus »Bristol-Myers Squibb Issues Statement on Celgene’s Settlement with Alvogen on Revlimid® Patent Litigation
Friday, March 29th 2019 at 5:33pm UTC NEW YORK–(BUSINESS WIRE)– Bristol-Myers Squibb Company (NYSE:BMY) today issued the following statement regarding Celgene’s (NASDAQ:CELG) settlement with Lotus Pharmaceutical Co., Ltd. and Alvogen Pine Brook, LLC (collectively, « Alvogen ») relating to patents for Revlimid: “We are pleased that Celgene has reached a settlement with …
Plus »Celgene Settles U.S. REVLIMID® Patent Litigation with Alvogen
Friday, March 29th 2019 at 4:00pm UTC Alvogen licensed to sell volume-limited amounts of generic lenalidomide in the U.S. beginning on a confidential date after the March 2022 date Celgene previously granted to Natco Alvogen also licensed to sell generic lenalidomide in the U.S. without volume limitation beginning on January …
Plus »
